Amgen To Webcast Investor Calls At ESMO 2020

Rhea-AI Summary

Amgen will host two webcast investor calls during the ESMO 2020 Virtual Congress. The first call is scheduled for September 20, 2020, at 11:00 a.m. PDT, where Dr. David M. Reese will discuss Phase 1 data on the KRAS^G12C inhibitor, sotorasib (AMG 510). The second call is on September 21, at 1:00 p.m. PDT, focusing on a bispecific T-cell engager targeting PSMA. These webcasts will be available live and archived on Amgen's website for at least 90 days, making it accessible to investors and the public.

THOUSAND OAKS, Calif., Sept. 16, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host two webcast calls for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2020 Virtual Congress. On Sunday, Sept. 20, 2020, at 11:00 a.m. PDT,  David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will discuss Phase 1 data being presented on the Company's investigational KRAS^G12C inhibitor sotorasib (AMG 510). On Monday, Sept. 21, at 1:00 p.m. PDT, David M. Reese, M.D., along with members of Amgen's clinical development team, will discuss the Phase 1 data being presented on the Company's investigational half-life extended bispecific T-cell engager (BiTE^®) immuno-oncology therapy targeting prostate-specific membrane antigen (PSMA). 

Live audio of the investor call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. 

The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.   

About Amgen 
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.  

CONTACT: Amgen, Thousand Oaks 
Megan Fox, 805-447-1423 (media)
Trish Rowland, 805-447-5631(media) 
Arvind Sood, 805-447-1060 (investors) 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-calls-at-esmo-2020-301132566.html

SOURCE Amgen

FAQ

What are the dates for Amgen's webcast calls at ESMO 2020?

Amgen's webcast calls are scheduled for September 20 and September 21, 2020.

Who will present at Amgen's webcast on September 20, 2020?

Dr. David M. Reese will present Phase 1 data on the KRAS^G12C inhibitor sotorasib (AMG 510).

What will be discussed during Amgen's September 21, 2020 webcast?

The September 21 webcast will cover Phase 1 data on a bispecific T-cell engager targeting PSMA.

How can I access Amgen's webcast calls?

The webcasts can be accessed live and archived on Amgen's website under the Investors section.

Will Amgen's webcasts be available for replay?

Yes, the webcasts will be archived and available for replay for at least 90 days after the events.